Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO & LEIDEN, Netherlands--(BUSINESS WIRE)--Santarus, Inc. (NASDAQ: SNTS) and Pharming Group NV (NYSE Euronext: PHARM) announced that new data from a pivotal Phase III clinical study with RUCONEST® (recombinant human C1 esterase inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) were featured in a poster presentation yesterday at the European Academy of Allergy and Clinical Immunology (EAACI) & World Allergy Organization (WAO) World Allergy & Asthma Congress in Milan, Italy. The data indicate that the time to beginning of relief of symptoms in patients experiencing an acute attack of HAE was statistically significantly shorter with RUCONEST compared with placebo.
Help employers find you! Check out all the jobs and post your resume.
